Ischaemic Stroke clinical trials

Explore recruiting ischaemic stroke clinical trials.

Recruiting ischaemic stroke studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ischaemic Stroke trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicentre study evaluating the safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with a specific antidote.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

StroKE34 Study Protocol: a randomized Controlled Phase IIa trial of intra-arterial Cd34+ Cells in acute ischemic Stroke

Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, placebo-controlled, double-blind, single-ascending-dose, Phase 1a/b study to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous NTR-641 in healthy adults and patients with acute ischemic stroke

Austria

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe - SM

Netherlands, Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Ischaemic Stroke trials by city

Ischaemic Stroke in Toronto Ischaemic Stroke in Vancouver Ischaemic Stroke in Montreal Ischaemic Stroke in Calgary Ischaemic Stroke in Edmonton Ischaemic Stroke in Ottawa Ischaemic Stroke in Winnipeg Ischaemic Stroke in Quebec City Ischaemic Stroke in Hamilton Ischaemic Stroke in Kitchener Ischaemic Stroke in London Ischaemic Stroke in Halifax Ischaemic Stroke in New York Ischaemic Stroke in Los Angeles Ischaemic Stroke in Chicago Ischaemic Stroke in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease